Tamoxifen and chemotherapy for triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic or locally advanced triple negative breast cancer that has been treated with at least 2 prior therapies.
- Your tumor has a specific change in the TP53 gene, which will be checked by a special test.
- You are 18 years or older.
- You are in reasonably good health with adequate blood counts, liver and kidney function, and heart function.
- You are able to swallow pills and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests whether giving chemotherapy before surgery helps women with triple-negative breast cancer that is still local (not spread far). The goal is to see if this neoadjuvant approach improves outcomes.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
Hear when a new Anatomic Stage III Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.